Emanuel Petricoin and Lance Liotta, Co-Directors of Mason’s Center for Applied Proteomics and Molecular Medicine (CAPMM),received funding for: “Murtha Cancer Center Clinical Proteomics Platform – RPPA Assessment in the APOLLO Program.”
Petricoin and Liotta will:
1. Lead the RPPA discovery proteomics efforts in the Murtha Cancer Center Clinical Proteomics Platform. This includes receipt of tissue lysates, tissue sections or enriched cell preparations, and preparation of lysates, along with all aspects of the RPPA workflow including plating, printing, staining, and image-based data extraction. All data will be jointly shared and analyzed with APOLLO investigators;
2. Participate in the weekly executive APOLLO team meetings to review scientific and programmatic progress;
3. Provide scientific guidance and technical oversight for the RPPA capability as part of the Murtha Cancer Center Clinical Proteomics Platform;
4. Represent the scientific accomplishments of the Murtha Cancer Center Clinical Proteomics Platform at local, regional, and national scientific conferences;
5. Assist in preparation and delivery of technical and programmatic briefings as necessary;
6. Prepare technical quarterly and annual reports for the Murtha Cancer Center Clinical Proteomics Platform;
7. Coordinate and participate in weekly technical review meetings;
8. Meet with scientific staff weekly to review progress and plan next technical objectives for the Murtha Cancer Center Clinical Proteomics Platform;
9. Help prepare technical publications and presentations; and
10. Help develop new collaborative opportunities and sustainment of ongoing collaborations for enrichment of the Murtha Cancer Center Clinical Proteomics Platform translational impact.
The researchers received $281,319 from the Uniformed Services University of the Health Sciences on a subaward from the Henry M. Jackson Foundation for this project. Funding began in May 2022 and will end in late April 2023.